Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Axsome Therapeutics Investors Awaken to Positive Outcome in Phase 2 Narcolepsy Trial

Axsome Therapeutics shares traded 14% higher today after the company reported that its narcolepsy drug candidate AXS-12 achieved its primary endpoint in the Phase 2 CONCERT Study. This morning before U.S. markets opened, clinical-stage biopharmaceutical company Axsom...
Streetwise Reports | December 4, 2019 |

Axsome Therapeutics Shares Open 82% Higher on Phase 3 MDD Trial Outcome

Axsome Therapeutics shares reached a new 52-week high price today after the company reported that its AXS-05 drug achieved primary endpoint in the GEMINI Phase 3 trial in Major Depressive Disorder. The firm indicated that the positive results support a New Drug Application fil...
Streetwise Reports | December 17, 2019 |

Big Picture Outlook: Seat Belts Tightened

"Gold is money; everything else is credit." —J.P. Morgan Dating back to the mid-80s, and usually around the end of November, I begin to formulate strategies and portfolios looking out to the upcoming New Year, taking into account technical, fundamental and geopolitica...
Streetwise Reports | December 3, 2019 |

Is Gold Price Action Warning Of Imminent Monetary Collapse?

During the 2008 financial crisis the Fed significantly increased the US monetary base to keep the system from collapse. They are currently in a similar situation, and have done (is doing) the exact same thing. Here is a chart of the US monetary base to illustrate the simi...
Hubert Moolman | April 22, 2020 |

Buzz on the Bullboards: Markets React to Uncertainty Over US Election Outcome

(Screenshots via CNN video.) It has been a tumultuous time for the markets, from abrupt deep dips to relief rallies that saw effects to indexes on both sides of the border. US stock futures have been northing short of volatile in the last few days with the president...
Stockhouse Editorial | November 4, 2020 |

June 17th 2020, Crypto Chartbook: Failure equals big money

Failure equals big money If that be the case we’d be all rich trading the markets. No, what we are referring here to is pattern failure. Chart patterns have probabilities of how often they work. Most bet in favor of the favorable outcome of such patterns. ...
Korbinian Koller | June 17, 2020 |

Nov 17th 2019, Crypto Chartbook – Indicator divergence

Indicator divergence With a vast following of market speculators, we receive a consistent inflow of questions and comments about the market. Traders ask in our our telegram channel, in which we post our trades live, and via e mail as well as in our public appearances, ab...
Korbinian Koller | November 19, 2019 |

GBP/USD Daily Forecast – UK Retail Sales Slumps, BoE Up Next

GBP/USD is trading in a tight range just above the 1.3100 level but volatility is expected as the Bank of England announces their latest rate decision later in the day. Jignesh Davda UK Retail Sales Decline ...
FX Empire | December 20, 2019 |

PDS Biotech Collaborating with Merck in Phase 2 Cancer Trial

This morning PDS Biotechnology Corp. shares are trading 38% higher after reporting that it will enter into a clinical collaboration with Merck pairing the firm's PDS0101 with KEYTRUDA for patients with recurrent or metastatic head and neck cancer and high-risk HPV16 infection....
Streetwise Reports | October 4, 2019 |

NervGen: Are amazing human trial results leaking out?

“We are very excited! We are very, very excited!” So says Dr. Monica Perez, who is running the first human trial for a potential new wonder drug being developed by a tiny but well-financed life sciences start-up, NervGen Pharma Corp. ...
Knox Henderson | July 2, 2024 |
1 2 3 4 5 6 7 8 9 10 ...